OpenURL Connection Search

Select item for more details and to access through your institution.

Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS—Meet-URO 26 Study
Published in:
Clinical Genitourinary Cancer, 2024, v. 22, n. 5, p. N.PAG, doi. 10.1016/j.clgc.2024.102185
By:
- Fotia, Giuseppe;
- Saieva, Calogero;
- Lee-Ying, Richard;
- Patrikidou, Anna;
- Nuzzo, Pier Vitale;
- Zanardi, Elisa;
- Rossetti, Sabrina;
- Davidsohn, Matthew;
- Eid, Marc;
- El Zarif, Talal;
- McClure, Heather;
- Spinelli, Gian Paolo;
- Damassi, Alessandra;
- Murianni, Veronica;
- Vauchier, Charles;
- Oliveira, Thiago Martins;
- Malgeri, Andrea;
- Modesti, Mikol;
- Mestre, Ricardo Pereira;
- Valenca, Loana
Publication type:
Article
Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
Published in:
Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359231156147
By:
- Nuzzo, Pier Vitale;
- Ravera, Francesco;
- Saieva, Calogero;
- Zanardi, Elisa;
- Fotia, Giuseppe;
- Malgeri, Andrea;
- Rossetti, Sabrina;
- Valença, Loana Bueno;
- Oliveira, Thiago Martins;
- Vauchier, Charles;
- Pereira Mestre, Ricardo;
- Modesti, Mikol;
- Patrikidou, Anna;
- Pignata, Sandro;
- Procopio, Giuseppe;
- Fornarini, Giuseppe;
- De Giorgi, Ugo;
- Russo, Antonio;
- Francini, Edoardo
Publication type:
Article

Found: 2

Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS—Meet-URO 26 Study

Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.